Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Osteosarcoma, drawn from the whole corpus: 27 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No survival improvement since the 1980s; metastatic and relapsed disease ~20-30% survival.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
No recurrent druggable driver; genomic chaos.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Chemotherapy toxicity: cardiotoxicity, hearing loss, infertility, second cancers.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Rarity fragments trials; international cooperation (EURAMOS) needed for every question.
Nothing recorded yet.
Nothing recorded yet.
Background: FNCLCC grade (soft-tissue sarcoma). Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
Cabozantinib met the activity thresholds in both the Ewing sarcoma and osteosarcoma cohorts.
Regorafenib improved eight-week progression-free survival over placebo in relapsed osteosarcoma, with signals in the Ewing sarcoma and chondrosarcoma cohorts.
A milestone in how this cancer is treated.
Pembrolizumab produced objective responses mainly in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, with little activity in bone sarcomas.
15-year all-cause mortality among five-year survivors fell from 12.